ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

University of Sydney at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University of Sydney takes part in 4 sessions at ESMO 2026 in Madrid. Its work spans breast, prostate and skin cancers, alongside tumour testing. It examines ways to improve DNA testing success, reports overall survival results for fulvestrant and ipatasertib in metastatic breast cancer, and considers BRAF as a marker in early melanoma.

OrganizationESMO 2026 Attendance
University of Sydney
Sydney, Australia
University & institute
Public research university in Sydney, Australia, with a medical school and a national clinical trials centre.
Poster
Fri Oct 23
13:00–15:00
Adjust amplifiable FFPE DNA inputs to improve first-pass NGS success rate in solid tumours
ePoster session 17
Biomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Small-cell neuroendocrine prostate cancer (SCNEPC) emerging after starting treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Friday Poster Display session 5
Sarcoma, CNS, head & neck and rare cancersGenitourinary cancers
Talk
Mon Oct 26
08:30–08:45
Presentation by Expert 1: Mastering the mutation - BRAF as the sole biomarker of use in early melanoma
Too big to scale? NGS in the setting of melanoma
Melanoma & skin cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at University of Sydney

Tell us what you sell and we’ll find the people at University of Sydney most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction